<DOC>
	<DOCNO>NCT02297542</DOCNO>
	<brief_summary>This 5-year proposal randomize study split-virus influenza vaccine ( SVV ) high-dose ( HD ) vs. standard-dose ( SD ) formulation five influenza season define key determinant vaccine-mediated protection influenza immunologic mediator may enhance vaccination newly approve high-dose influenza vaccine old people</brief_summary>
	<brief_title>Immune Response High-Dose vs. Standard Dose Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Written inform consent provide participant 2 . Age 2040 year old underlying chronic disease age â‰¥65 year old 3 . Willing receive influenza vaccination 4 . Older cohort receive influenza vaccine previous influenza season 1 . Immunosuppressive disorder medication ( include oral prednisone dose &gt; 10 mg daily ) 2 . Have receive influenza vaccination past vaccinate due previous severe reaction influenza vaccine , egg , latex , thimerosol allergy , refusal vaccination 3 . Participant receive community available influenza vaccine approach influenza season 4 . Females pregnant Visit 1 ( pregnancy test administer female childbearing potential )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza Vaccine</keyword>
</DOC>